CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CDS2 (ImmuneEditome ID:8760)

1. Gene summary of enriched editing regions for CDS2

check button Gene summary
Gene informationGene symbol

CDS2

Gene ID

8760

GeneSynonyms-
GeneCytomap

20p12.3

GeneTypeprotein-coding
GeneDescriptionphosphatidate cytidylyltransferase 2|CDP-DAG synthase 2|CDP-DG synthase 2|CDP-DG synthetase 2|CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2|CDP-diglyceride diphosphorylase 2|CDP-diglyceride pyrophosphorylase 2|CDP-diglyceride synthase 2|CDP-diglyceride synthetase 2|CDS 2|CTP:phosphatidate cytidylyltransferase 2
GeneModificationdate20230329
UniprotIDO95674
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr20:5194844-5195208:+ENST00000460006.4ENSG00000101290.12CDS2UTR3MIRbchr20:5194844-5195208:+.alignment


Top

2. Tumor-specific enriched editing regions for CDS2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr20:5194844-5195208:+BRCAEER3.8760e-11image
ENSG00000101290.12,CDS2BRCAEAG3.4332e-11image
ENSG00000101290.12,CDS2KICHEAG4.0008e-05image
chr20:5194844-5195208:+KIRCEER1.0694e-03image
ENSG00000101290.12,CDS2KIRCEAG9.1172e-04image
chr20:5194844-5195208:+KIRPEER4.3996e-02image
ENSG00000101290.12,CDS2KIRPEAG4.3996e-02image
chr20:5194844-5195208:+LUSCEER1.2017e-03image
ENSG00000101290.12,CDS2LUSCEAG1.2017e-03image
chr20:5194844-5195208:+THCAEER9.6342e-03image
ENSG00000101290.12,CDS2THCAEAG9.6342e-03image
ENSG00000101290.12,CDS2UCECEAG1.6699e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000101290.12,CDS2CHOLPathEAG5.5540e-032.7678e-020.4690image
chr20:5194844-5195208:+CHOLPathEER5.5540e-032.7678e-020.4690image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for CDS2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr20:5194844-5195208:+GBMEERENSG00000188015,S100A30.31287.5743e-032.5111e-100.4904imageNNNAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr20:5194844-5195208:+ESCAEERENSG00000197646,PDCD1LG20.27314.3699e-025.5308e-110.4984imageNNPDCD1LG2Macrophages_M1GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr20:5194844-5195208:+PCPGEERENSG00000143575,HAX10.43559.2982e-064.6019e-100.4662imageNNHAX1T_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr20:5194844-5195208:+PCPGEERENSG00000269427,CTC-429P9.1-0.42232.4599e-051.9146e-08-0.4250imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr20:5194844-5195208:+PCPGEERENSG00000143256,PFDN20.40177.9078e-051.2886e-100.4791imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr20:5194844-5195208:+PCPGEERENSG00000159377,PSMB40.39721.0412e-049.8684e-110.4817imageNNPSMB4T_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr20:5194844-5195208:+PCPGEERENSG00000143198,MGST30.39251.1015e-046.3557e-100.4628imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr20:5194844-5195208:+PCPGEERENSG00000159352,PSMD40.38352.0634e-041.2695e-070.4018imageNNPSMD4T_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr20:5194844-5195208:+PCPGEERENSG00000268087,CTC-429P9.2-0.38052.4381e-041.4064e-09-0.4544imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr20:5194844-5195208:+PCPGEERENSG00000266472,MRPS210.37502.8736e-041.2933e-080.4296imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEDGEHOG_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for CDS2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr20:5194844-5195208:+
ESCAEERIRENSG00000104613.7chr819845662:19845797:19849161:19849239-0.35763.9624e-037.3146e-08-0.4573imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000101290.12,CDS2
ESCAEAGIRENSG00000104613.7chr819845662:19845797:19849161:19849239-0.34616.8955e-031.0448e-07-0.4508imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DIS3L2;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000101290.12,CDS2
PCPGEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.41661.4610e-047.5978e-10-0.4609imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184PRKCSHT_cells_CD4_memory_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000101290.12,CDS2
PCPGEAGIRENSG00000008853.12chr823004043:23006145:23006727:230077460.30896.1401e-038.8568e-070.4041imageNADAR;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RTCB;SF3B4;SLTM;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1NAGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000101290.12,CDS2
PCPGEAGIRENSG00000169592.10chr1630001211:30001530:30004567:30004657-0.38806.2829e-046.4743e-08-0.4127imageNAIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr20:5194844-5195208:+
PCPGEERIRENSG00000008853.12chr823004043:23006145:23006727:230077460.30896.7905e-038.8568e-070.4041imageNNNAGSVA_HALLMARK_MITOTIC_SPINDLE
chr20:5194844-5195208:+
PCPGEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.41661.6758e-047.5978e-10-0.4609imageNNPRKCSHT_cells_CD4_memory_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr20:5194844-5195208:+
PCPGEERIRENSG00000169592.10chr1630001211:30001530:30004567:30004657-0.38807.1716e-046.4743e-08-0.4127imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr20:5194844-5195208:+
SKCMEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.43473.4034e-152.9966e-18-0.4081imageNNPRKCSHT_cells_CD8GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000101290.12,CDS2
SKCMEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.43473.9772e-152.9966e-18-0.4081imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184PRKCSHT_cells_CD8GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for CDS2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr20:5194844-5195208:+BLCAEERB_cells_naive1.9185e-020.2036image
ENSG00000101290.12,CDS2BLCAEAGB_cells_naive1.8280e-020.2052image
chr20:5194844-5195208:+BRCAEERT_cells_CD4_memory_activated1.2721e-040.1320image
ENSG00000101290.12,CDS2BRCAEAGT_cells_CD4_memory_activated1.3897e-040.1312image
chr20:5194844-5195208:+CESCEERNK_cells_resting5.9267e-030.2357image
ENSG00000101290.12,CDS2CESCEAGNK_cells_resting5.9267e-030.2357image
chr20:5194844-5195208:+CHOLEERB_cells_memory4.8600e-040.6809image
ENSG00000101290.12,CDS2CHOLEAGB_cells_memory4.8600e-040.6809image
chr20:5194844-5195208:+COADEERT_cells_follicular_helper8.2218e-030.2283image
ENSG00000101290.12,CDS2COADEAGT_cells_follicular_helper7.7034e-030.2284image
ENSG00000101290.12,CDS2DLBCEAGMacrophages_M22.9949e-020.4856image
chr20:5194844-5195208:+ESCAEERT_cells_CD4_naive1.4140e-040.3029image
ENSG00000101290.12,CDS2ESCAEAGT_cells_CD4_naive1.9486e-040.2959image
chr20:5194844-5195208:+GBMEERMacrophages_M04.6624e-05-0.3282image
ENSG00000101290.12,CDS2GBMEAGMacrophages_M04.6624e-05-0.3282image
chr20:5194844-5195208:+HNSCEERMacrophages_M13.4270e-050.2407image
ENSG00000101290.12,CDS2HNSCEAGMacrophages_M13.4270e-050.2407image
ENSG00000101290.12,CDS2KICHEAGDendritic_cells_activated4.8321e-02-0.2960image
chr20:5194844-5195208:+KIRCEERT_cells_follicular_helper7.4738e-040.1767image
ENSG00000101290.12,CDS2KIRCEAGT_cells_follicular_helper1.5779e-030.1657image
chr20:5194844-5195208:+KIRPEERT_cells_CD84.3440e-030.1870image
ENSG00000101290.12,CDS2KIRPEAGT_cells_CD84.3440e-030.1870image
chr20:5194844-5195208:+LGGEERT_cells_CD4_naive3.5099e-03-0.1293image
ENSG00000101290.12,CDS2LGGEAGT_cells_CD4_naive3.5099e-03-0.1293image
chr20:5194844-5195208:+LIHCEERT_cells_regulatory_(Tregs)1.5388e-02-0.2146image
ENSG00000101290.12,CDS2LIHCEAGT_cells_regulatory_(Tregs)1.5388e-02-0.2146image
chr20:5194844-5195208:+LUADEERT_cells_regulatory_(Tregs)2.0142e-020.1271image
ENSG00000101290.12,CDS2LUADEAGT_cells_regulatory_(Tregs)2.3639e-020.1238image
chr20:5194844-5195208:+LUSCEERT_cells_follicular_helper1.8907e-020.1308image
ENSG00000101290.12,CDS2LUSCEAGT_cells_follicular_helper1.8907e-020.1308image
chr20:5194844-5195208:+MESOEERMast_cells_resting4.8253e-03-0.3747image
ENSG00000101290.12,CDS2MESOEAGMast_cells_resting4.8253e-03-0.3747image
chr20:5194844-5195208:+OVEERMacrophages_M06.8640e-04-0.2448image
ENSG00000101290.12,CDS2OVEAGMacrophages_M03.9749e-03-0.2075image
chr20:5194844-5195208:+PAADEERMacrophages_M11.4377e-020.2287image
ENSG00000101290.12,CDS2PAADEAGMacrophages_M11.4377e-020.2287image
chr20:5194844-5195208:+PCPGEERT_cells_CD4_memory_resting6.1439e-03-0.2151image
ENSG00000101290.12,CDS2PCPGEAGT_cells_CD4_memory_resting6.1439e-03-0.2151image
ENSG00000101290.12,CDS2PRADEAGMacrophages_M21.4562e-030.1623image
ENSG00000101290.12,CDS2READEAGT_cells_follicular_helper1.8908e-020.3023image
chr20:5194844-5195208:+SKCMEERT_cells_CD88.2148e-090.2766image
ENSG00000101290.12,CDS2SKCMEAGT_cells_CD88.2148e-090.2766image
chr20:5194844-5195208:+STADEERNK_cells_activated2.3916e-020.1295image
ENSG00000101290.12,CDS2STADEAGNK_cells_activated1.1772e-020.1429image
chr20:5194844-5195208:+TGCTEERMacrophages_M21.2799e-08-0.5409image
ENSG00000101290.12,CDS2TGCTEAGMacrophages_M21.2799e-08-0.5409image
chr20:5194844-5195208:+THCAEERT_cells_regulatory_(Tregs)4.2003e-020.0980image
ENSG00000101290.12,CDS2THCAEAGT_cells_regulatory_(Tregs)4.2003e-020.0980image
chr20:5194844-5195208:+THYMEERT_cells_gamma_delta1.4471e-020.2891image
ENSG00000101290.12,CDS2THYMEAGT_cells_gamma_delta1.4471e-020.2891image
ENSG00000101290.12,CDS2UCECEAGB_cells_memory8.7122e-040.4946image
chr20:5194844-5195208:+UVMEERT_cells_CD88.9999e-030.2977image
ENSG00000101290.12,CDS2UVMEAGT_cells_CD88.9999e-030.2977image


Top

6. Enriched editing regions and immune gene sets for CDS2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000101290.12,CDS2STADEAG5.9316e-03image4.4830e-02-0.1140image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr20:5194844-5195208:+BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.0725e-030.2816image
ENSG00000101290.12,CDS2BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG7.9138e-040.2886image
ENSG00000101290.12,CDS2BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6285e-150.2703image
chr20:5194844-5195208:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.9638e-160.2724image
chr20:5194844-5195208:+CESCGSVA_HALLMARK_COMPLEMENTEER5.8111e-040.2923image
ENSG00000101290.12,CDS2CESCGSVA_HALLMARK_COMPLEMENTEAG5.8111e-040.2923image
chr20:5194844-5195208:+CHOLGSVA_HALLMARK_PEROXISOMEEER1.9835e-03-0.6223image
ENSG00000101290.12,CDS2CHOLGSVA_HALLMARK_PEROXISOMEEAG1.9835e-03-0.6223image
chr20:5194844-5195208:+COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5826e-020.1933image
chr20:5194844-5195208:+ESCAGSVA_HALLMARK_HYPOXIAEER4.5811e-030.2280image
ENSG00000101290.12,CDS2ESCAGSVA_HALLMARK_HYPOXIAEAG4.8215e-030.2260image
ENSG00000101290.12,CDS2GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.1948e-03-0.2408image
chr20:5194844-5195208:+GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.1948e-03-0.2408image
ENSG00000101290.12,CDS2HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.8917e-050.2336image
chr20:5194844-5195208:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.8917e-050.2336image
ENSG00000101290.12,CDS2KICHGSVA_HALLMARK_MTORC1_SIGNALINGEAG5.4826e-04-0.4949image
chr20:5194844-5195208:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2069e-050.2281image
ENSG00000101290.12,CDS2KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.8358e-050.2099image
ENSG00000101290.12,CDS2KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0492e-02-0.1681image
chr20:5194844-5195208:+KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0492e-02-0.1681image
ENSG00000101290.12,CDS2LAMLGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.3133e-030.2758image
chr20:5194844-5195208:+LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.7061e-060.2105image
ENSG00000101290.12,CDS2LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.7061e-060.2105image
chr20:5194844-5195208:+LIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.4906e-040.3024image
ENSG00000101290.12,CDS2LIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.4906e-040.3024image
ENSG00000101290.12,CDS2LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.2927e-030.1559image
chr20:5194844-5195208:+LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3526e-030.1601image
ENSG00000101290.12,CDS2LUSCGSVA_HALLMARK_PEROXISOMEEAG1.4154e-020.1366image
chr20:5194844-5195208:+LUSCGSVA_HALLMARK_PEROXISOMEEER1.4154e-020.1366image
chr20:5194844-5195208:+MESOGSVA_HALLMARK_G2M_CHECKPOINTEER3.8412e-03-0.3836image
ENSG00000101290.12,CDS2MESOGSVA_HALLMARK_G2M_CHECKPOINTEAG3.8412e-03-0.3836image
ENSG00000101290.12,CDS2OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.2156e-04-0.2745image
chr20:5194844-5195208:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7941e-040.2692image
chr20:5194844-5195208:+PAADGSVA_HALLMARK_SPERMATOGENESISEER1.2148e-02-0.2342image
ENSG00000101290.12,CDS2PAADGSVA_HALLMARK_SPERMATOGENESISEAG1.2148e-02-0.2342image
chr20:5194844-5195208:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3664e-040.2791image
ENSG00000101290.12,CDS2PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.3664e-040.2791image
ENSG00000101290.12,CDS2PRADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.3449e-03-0.1635image
ENSG00000101290.12,CDS2SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.3762e-040.2765image
chr20:5194844-5195208:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.3775e-040.2765image
chr20:5194844-5195208:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.7782e-120.3266image
ENSG00000101290.12,CDS2SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.7782e-120.3266image
ENSG00000101290.12,CDS2STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.0710e-04-0.2092image
chr20:5194844-5195208:+STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER6.8974e-03-0.1547image
chr20:5194844-5195208:+TGCTGSVA_HALLMARK_ANGIOGENESISEER4.0750e-08-0.5247image
ENSG00000101290.12,CDS2TGCTGSVA_HALLMARK_ANGIOGENESISEAG4.0750e-08-0.5247image
chr20:5194844-5195208:+THCAGSVA_HALLMARK_GLYCOLYSISEER4.1333e-030.1379image
ENSG00000101290.12,CDS2THCAGSVA_HALLMARK_GLYCOLYSISEAG4.1333e-030.1379image
chr20:5194844-5195208:+THYMGSVA_HALLMARK_NOTCH_SIGNALINGEER1.9781e-030.3611image
ENSG00000101290.12,CDS2THYMGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.9781e-030.3611image
ENSG00000101290.12,CDS2UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.4280e-020.3274image
ENSG00000101290.12,CDS2UVMGSVA_HALLMARK_PEROXISOMEEAG2.4625e-020.2577image
chr20:5194844-5195208:+UVMGSVA_HALLMARK_PEROXISOMEEER2.4625e-020.2577image


Top

7. Enriched editing regions and drugs for CDS2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr20:5194844-5195208:+BLCACI.1040EER3.1824e-03-0.2549image
ENSG00000101290.12,CDS2BLCACI.1040EAG2.8689e-03-0.2576image
chr20:5194844-5195208:+BRCAAxitinibEER1.2499e-050.1504image
ENSG00000101290.12,CDS2BRCAAxitinibEAG1.8170e-050.1475image
chr20:5194844-5195208:+CESCGefitinibEER1.2414e-03-0.2751image
ENSG00000101290.12,CDS2CESCGefitinibEAG1.2414e-03-0.2751image
ENSG00000101290.12,CDS2CHOLBleomycinEAG1.3635e-02-0.5175image
chr20:5194844-5195208:+CHOLBleomycinEER1.3635e-02-0.5175image
ENSG00000101290.12,CDS2DLBCBleomycinEAG5.3145e-03-0.5984image
chr20:5194844-5195208:+ESCADocetaxelEER3.0016e-04-0.2884image
ENSG00000101290.12,CDS2ESCADocetaxelEAG2.8814e-04-0.2883image
ENSG00000101290.12,CDS2GBMErlotinibEAG8.2086e-05-0.3180image
chr20:5194844-5195208:+GBMErlotinibEER8.2086e-05-0.3180image
chr20:5194844-5195208:+HNSCMetforminEER3.9335e-03-0.1688image
ENSG00000101290.12,CDS2HNSCMetforminEAG3.9335e-03-0.1688image
ENSG00000101290.12,CDS2KICHBicalutamideEAG1.6448e-03-0.4560image
ENSG00000101290.12,CDS2KIRCFH535EAG1.7643e-040.1962image
chr20:5194844-5195208:+KIRCFH535EER8.6709e-050.2051image
chr20:5194844-5195208:+KIRPBMS.536924EER5.9290e-04-0.2253image
ENSG00000101290.12,CDS2KIRPBMS.536924EAG5.9290e-04-0.2253image
ENSG00000101290.12,CDS2LAMLDasatinibEAG7.7808e-05-0.3358image
ENSG00000101290.12,CDS2LGGAxitinibEAG7.2905e-050.1751image
chr20:5194844-5195208:+LGGAxitinibEER7.2905e-050.1751image
chr20:5194844-5195208:+LIHCGSK.650394EER2.2320e-020.2026image
ENSG00000101290.12,CDS2LIHCGSK.650394EAG2.2320e-020.2026image
ENSG00000101290.12,CDS2LUADCEP.701EAG9.7838e-03-0.1412image
chr20:5194844-5195208:+LUADCEP.701EER7.8576e-03-0.1452image
chr20:5194844-5195208:+LUSCAP.24534EER2.6204e-030.1672image
ENSG00000101290.12,CDS2LUSCAP.24534EAG2.6204e-030.1672image
ENSG00000101290.12,CDS2OVABT.263EAG6.6746e-050.2844image
chr20:5194844-5195208:+OVABT.263EER3.4101e-050.2966image
chr20:5194844-5195208:+PCPGAxitinibEER4.5755e-040.2730image
ENSG00000101290.12,CDS2PCPGAxitinibEAG4.5755e-040.2730image
ENSG00000101290.12,CDS2PRADEmbelinEAG2.1024e-040.1886image
ENSG00000101290.12,CDS2READBortezomibEAG7.9192e-03-0.3397image
ENSG00000101290.12,CDS2SARCMethotrexateEAG8.2557e-05-0.3089image
chr20:5194844-5195208:+SARCMethotrexateEER8.2589e-05-0.3089image
chr20:5194844-5195208:+SKCMGDC.0449EER3.1538e-08-0.2659image
ENSG00000101290.12,CDS2SKCMGDC.0449EAG3.1538e-08-0.2659image
ENSG00000101290.12,CDS2STADAP.24534EAG3.6056e-040.2014image
chr20:5194844-5195208:+STADImatinibEER2.7070e-040.2074image
ENSG00000101290.12,CDS2TGCTKIN001.135EAG3.4176e-100.5865image
chr20:5194844-5195208:+TGCTKIN001.135EER3.4176e-100.5865image
ENSG00000101290.12,CDS2THCAEmbelinEAG4.9890e-070.2393image
chr20:5194844-5195208:+THCAEmbelinEER4.9890e-070.2393image
ENSG00000101290.12,CDS2THYMMetforminEAG1.0064e-030.3822image
chr20:5194844-5195208:+THYMMetforminEER1.0064e-030.3822image
ENSG00000101290.12,CDS2UCECCGP.082996EAG2.8857e-02-0.3374image
chr20:5194844-5195208:+UVMCisplatinEER2.1082e-03-0.3474image
ENSG00000101290.12,CDS2UVMCisplatinEAG2.1082e-03-0.3474image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType